In Vivo Manipulation of Dendritic Cells Overcomes Tolerance to Unmodified Tumor-Associated Self Antigens and Induces Potent Antitumor Immunity
Authors:
- 1 March 2005
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 174 (5) , 2645-2652
Abstract
Most tumor-associated Ags are self proteins that fail to elicit a T cell response as a consequence of immune tolerance. Dendritic cells (DCs) generated ex vivo have been used to break tolerance against such self Ags; however, in vitro manipulation of DCs is cumbersome and difficult to control, resulting in vaccines of variable potency. To address this problem we developed a method for loading and activating DCs, in situ, by first directing sufficient numbers of DCs to peripheral tissues using Flt3 ligand and then delivering a tumor-associated Ag and oligonucleotide containing unmethylated CG motifs to these tissues. In this study, we show in three different tumor models that this method can overcome tolerance and induce effective antitumor immunity. Vaccination resulted in the generation of CD8+ T and NK cell effectors that mediated durable tumor responses without attacking normal tissues. These findings demonstrate that unmodified tumor-associated self Ags can be targeted to DCs in vivo to induce potent systemic antitumor immunity.Keywords
This publication has 39 references indexed in Scilit:
- In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell VaccinationJournal of Experimental Medicine, 2004
- Dendritic cells transduced with TAT protein transduction domain‐containing tyrosinase‐related protein 2 vaccinate against murine melanomaEuropean Journal of Immunology, 2003
- Toll‐like receptor expression in murine DC subsets: lack of TLR7 expression by CD8α+ DC correlates with unresponsiveness to imidazoquinolinesEuropean Journal of Immunology, 2003
- Characterization of a new subpopulation of mouse CD8α+ B220+ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potentialBlood, 2002
- Induction of tumor-specific protective immunity by in situ Langerhans cell vaccineNature Biotechnology, 2002
- Dendritic Cells in Cancer ImmunotherapyAnnual Review of Immunology, 2000
- Immunobiology of Dendritic CellsAnnual Review of Immunology, 2000
- The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissuesSeminars in Cancer Biology, 1999
- Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 MelanomaJournal of Experimental Medicine, 1997
- Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified.Journal of Experimental Medicine, 1996